1stOncology™: Cancer Intelligence Service – Page 12575 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Physicians’ Education Resource® Presents the 14th Annual New York Lung Cancers Symposium®

On August 28, 2019 Physicians’ Education Resource (PER), a worldwide leading resource for continuing medical education (CME), reported that it will host the 14th Annual New York Lung Cancers Symposium on Saturday, Nov. 9 at the New York Marriott Marquis in New York City (Press release, Physicians’ Education Resource, AUG 28, 2019, View Source [SID1234539074]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

This year’s program will be once again be co-chaired by renowned oncologists, Mark G. Kris, M.D., attending physician, thoracic oncology service, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center; and Roman Perez-Soler, M.D., chairman, department of oncology, Montefiore Medical Center, professor of medicine and molecular pharmacology, deputy cancer center director, Albert Einstein College of Medicine.

"We are excited to host our annual New York Lung Cancers Symposium in New York City again this year," said Phil Talamo, president of PER. "We look forward to presenting this exciting meeting, centered on lung cancers, that will foster collaboration between members of the multidisciplinary oncology team."

The 14th Annual New York Lung Cancers Symposium is a one-day educational and interactive program that provides a comprehensive overview of lung cancer diagnosis and multidisciplinary treatment. Experts will discuss optimal approaches for early-stage and locally advanced disease as well as present the latest data on immunotherapy and targeted agents in metastatic lung cancers. Attendees will also get a preview of upcoming advances in local and systemic therapies for thoracic malignancies. As with previous years, this meeting will feature a special breakfast session for nurse practitioners and physicians’ assistants that will provide opportunities for learning and networking with the faculty about their most challenging cases.

Accredited by the Accreditation Council for Continuing Medical Education and approved by the California Board of Registered Nursing, this symposium provides attendees with the opportunity to earn up to 8.25 AMA PRA Category 1 Credits and nursing contact hours.

Sensei Biotherapeutics to Present at Citi 14th Annual Biotech Conference

On August 28, 2019 Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, reported that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will participate in a private company panel discussion at the Citi 14th Annual Biotech Conference on Wednesday, September 4, 2019 at 3:45 p.m. ET in Boston, MA (Press release, Sensei Biotherapeutics, AUG 28, 2019, View Source [SID1234539073]).

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

On August 28, 2019 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a leading U.S.-based multi-platform clinical-stage gene therapy company, reported participation at the following upcoming conferences (Press release, Rocket Pharmaceuticals, AUG 28, 2019, View Source [SID1234539072]):

Citi’s 14ᵗʰ Annual Biotech Conference
Wednesday, September 4, 2019
Baird’s 2019 Global Healthcare Conference
Gaurav Shah, M.D., President and CEO, is scheduled to present on Thursday, September 5, 2019, at 12:15 p.m. Eastern Time.
Morgan Stanley’s 17th Annual Global Healthcare Conference
Gaurav Shah, M.D., President and CEO, is scheduled to present on Wednesday, September 11, 2019, at 11:40 a.m. Eastern Time
Oppenheimer’s Fall Summit Focused on Specialty Pharma and Rare Disease Companies
Monday, September 23, 2019
Ladenburg Thalmann’s 2019 Healthcare Conference
Gaurav Shah, M.D., President and CEO, is scheduled to present on Tuesday, September 24, 2019, at 12:00 p.m. Eastern Time
A live audio webcast of the presentations will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.

PharmaCyte Biotech Confirms Dr. Manuel Hidalgo Will Be Principal Investigator for Clinical Trial in Pancreatic Cancer

On August 28, 2019 PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, reported that nationally and internationally renowned clinician and oncologist, Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center (Press release, PharmaCyte Biotech, AUG 28, 2019, View Source [SID1234539071]).

Dr. Hidalgo, a leading physician-scientist who specializes in pancreatic cancer and drug development, was recently appointed Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. Previously, Dr. Hidalgo was a Professor of Medicine at the Harvard Medical School and the Chief of the Division of Hematology Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center.

Dr. Hidalgo commented, "With PharmaCyte proceeding with the GMP production of the clinical trial product for its LAPC trial, I am more excited than ever to be a part of PharmaCyte’s clinical trial team. I remain enthusiastic about being the PI for the trial. I am also optimistic about the potential that PharmaCyte’s treatment may hold for patients suffering from LAPC and possibly other types of solid cancerous tumors. For example, PharmaCyte’s therapy for cancers involving the pancreas, liver and breast may offer an effective way to specifically target those cancers with little to no side effects from the chemotherapy."

TRACON Pharmaceuticals To Present At The RHK Capital 4th Annual Disruptive Growth Conference Hosted By Reed Smith

On August 28, 2019 TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration through our license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., reported that Charles Theuer, M.D., Ph.D., President and CEO, will present at the 4th annual Disruptive Growth Conference in New York on Wednesday, September 4th, at 1:40 PM EDT (Press release, Tracon Pharmaceuticals, AUG 28, 2019, View Source [SID1234539070]).

To access a live webcast of the presentation, please visit the "Events and Presentations" page within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.